secwatch.observer — SEC 8-K summary
======================================

Issuer:     InfuSystem Holdings, Inc (INFU)
CIK:        0001337013
Form:       8-K
Filed at:   2024-09-11T23:59:59+00:00
Accession:  0001628280-24-040073
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InfuSystem and Sanara secure exclusive US distribution deal for ChemoMouthpiece oral cryotherapy device
--------------------------------------------------------------------------------

- SI Technologies, a 50/50 JV between InfuSystem and Sanara, will be exclusive US distributor of ChemoMouthpiece's FDA 510(k)-cleared oral mucositis device.
- Sanara invested $5 million for a 6.6% ownership stake in ChemoMouthpiece; SI Technologies has a purchase option on the US business through January 2029.
- Product targets 500,000–1,000,000 annual oral mucositis patients; estimated US market exceeds $600 million.
- InfuSystem's existing oncology sales force will market the device to ~3,000 cancer centers.
- AMA issued a new CPT code (effective July 2024) for reimbursement of the oral cryotherapy procedure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024040073/0001628280-24-040073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1337013/000162828024040073/infu-20240911.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-040073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer